Changxian Shen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6065440/publications.pdf

Version: 2024-02-01

35 papers	1,107 citations	516710 16 h-index	526287 27 g-index
35 all docs	35 docs citations	35 times ranked	1837 citing authors

#	Article	IF	Citations
1	FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1317-1323.	6.4	274
2	Gene silencing by adenovirusâ€delivered siRNA. FEBS Letters, 2003, 539, 111-114.	2.8	176
3	TOR Signaling Is a Determinant of Cell Survival in Response to DNA Damage. Molecular and Cellular Biology, 2007, 27, 7007-7017.	2.3	83
4	Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks. Cancer Research, 2013, 73, 3393-3401.	0.9	78
5	Molecular imaging of proliferation in vivo: Positron emission tomography with [18F]fluorothymidine. Methods, 2009, 48, 205-215.	3.8	49
6	The mTOR pathway negatively controls ATM by up-regulating miRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11869-11874.	7.1	43
7	Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer Gene Therapy, 2003, 10, 403-410.	4.6	39
8	Inhibiting BRAF Oncogeneâ€“Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Clinical Cancer Research, 2019, 25, 4749-4760.	7.0	39
9	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4641-E4647.	7.1	36
10	Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Scientific Reports, 2017, 7, 1535.	3.3	30
11	Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes and Development, 2015, 29, 1707-1720.	5.9	29
12	Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy. Clinical Cancer Research, 2020, 26, 3740-3750.	7.0	29
13	Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair. Nucleic Acids Research, 2021, 49, 11067-11082.	14.5	26
14	P53 suppresses ribonucleotide reductase via inhibiting mTORC1. Oncotarget, 2017, 8, 41422-41431.	1.8	24
15	LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirusâ€“negative Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2019, 18, 1025-1035.	4.1	20
16	EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia. Clinical Cancer Research, 2020, 26, 669-678.	7.0	18
17	Targeting bcl-2 by Triplex-Forming Oligonucleotideâ€”A Promising Carrier for Geneâ€“Radiotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 17-26.	1.0	17
18	Adenovirus-Delivered siRNA. , 2004, 252, 523-532.		16

#	Article	IF	Citations
19	Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatric Blood and Cancer, 2015, 62, 1768-1774.	1.5	15
20	FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3â€“FOXO1 Fusion Gene. Clinical Cancer Research, 2014, 20, 3884-3895.	7.0	12
21	Pro-apoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells. Anticancer Research, 2009, 29, 1423-8.	1.1	11
22	Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy. Annals of Translational Medicine, 2021, 9, 1596-1596.	1.7	9
23	Liposomal Delivery of Antisense Oligonucleotides for Efficient Downregulation of Bcl-2 and Induction of Apoptosis. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 281-289.	1.0	8
24	mTOR Signaling Upregulates CDC6 via Suppressing miR-3178 and Promotes the Loading of DNA Replication Helicase. Scientific Reports, 2019, 9, 9805.	3.3	8
25	Regulation of DNA duplication by the mTOR signaling pathway. Cell Cycle, 2021, 20, 742-751.	2.6	6
26	Targeting FANCD2 for therapy sensitization. Oncotarget, 2014, 5, 3426-3427.	1.8	5
27	Chromosome instability and tumor lethality suppression in carcinogenesis. Journal of Cellular Biochemistry, 2008, 105, 1327-1341.	2.6	3
28	Deregulation of AKTâ€“mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma. Molecular Cancer Research, 2022, 20, 425-433.	3.4	3
29	Abstract 4437: Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double strand breaks.. , 2013, , .		1
30	Abstract LB-192: DNA damage checkpoints control spindle assembly checkpoint by regulating Mad2. , 2011, , .		0
31	Abstract 2535: Regulation of Chk1 by the mTOR pathway is essential for cancer cells to complete DNA replication in response to replication stress. , 2012, , .		0
32	Abstract LB-149: Sustained activity of the mTOR pathway is required for DNA damage-induced up-regulation of RRM2 in cancer cells.. , 2013, , .		0
33	EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML). Blood, 2016, 128, 2689-2689.	1.4	0
34	EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2546-2546.	1.4	0
35	Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer. , 2020, , .		0